Video

Dr. Jones on the Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in CRC

Jeremy C. Jones, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in colorectal cancer.

Jeremy C. Jones, MD, hematologist/oncologist, Mayo Clinic, discusses the risk of interstitial lung disease (ILD) with fam-trastuzumab deruxtecan-nxki (Enhertu) in colorectal cancer (CRC).

Initial findings from the phase 2 DESTINY-CRC01 trial demonstrated a 45.3% confirmed objective response rate with trastuzumab deruxtecan in patients with HER2-positive metastatic CRC. Regarding safety, 6% (n = 5) of patients developed ILD; 2 of these cases were grade 5.

As such, close monitoring for ILD is required when using trastuzumab deruxtecan for patients with CRC. Moreover, early intervention with steroids could mitigate the toxicity, Jones explains. In gastrointestinal cancers, ILD is not a common adverse effect associated with available therapies, Jones says. However, the promising efficacy observed with trastuzumab deruxtecan in HER2-positive CRC will likely outweigh the ILD-associated risks of the agent, concludes Jones.

Related Videos
Dr Sekkeres on the Association Between Smoking and Disease Progression in MDS
Lori Muffly, MD
Pooja Phull, MD
Eric Winer, MD
Jennifer Effie Amengual, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024..
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.